Comparison Between Treatments of Oligohydramnios
ConditionOligohydramnios
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-35
SponsorKafrelsheikh University
About this trial
Based on previous studies, Both sildenafil and L-arginine helped to improve idiopathic oligohydramnios.
In this study, Level of improvment of oligohydramnios will be compared. As well as, NICU admission to neonates of pregnancies complicated by idiopathic oligohydramnios. The end goal is to help physicians use the best drug for their patients.
Eligibility criteria
Qualifiers
Pregnant women with gestational age between 26-37 weeks
Pregnant women whose age is < 35 years
Woman with other indication for elective caesarean section.
Women carrying a single fetus with no major anomalies.
Disqualifiers
Women complaining of other obstetric disorder such as, PPROM, preeclampsia, or diabetes.
Women with chronic illness such as, chronic hypertension, autoimmune disease or kidney disease.
Women who received other treatments for oligohydramnios in current pregnancy.
Women who smoke.
Trial design
Treatments tested in this trial
- Sildenafil 25 MG
- L-Arginine, 1000 Mg Oral Tablet
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov